Frailty and comorbidity in predicting community COVID-19 mortality in the UK 1

Biobank: the effect of sampling 2

3

4 Jonathan K. L. Mak^{1*}, Ralf Kuja-Halkola¹, Yunzhang Wang¹, Sara Hägg¹, Juulia Jylhävä¹

5

6 ¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,

- 7 Sweden
- 8

9 *Corresponding author

- 10 Jonathan K. L. Mak
- 11 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A,
- 12 171 65 Stockholm, Sweden
- 13 Email: jonathan.mak@ki.se
- 14
- 15 Word count: Abstract: 244; Main text: 3164

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 Abstract

Frailty has been linked to an increased risk of coronavirus disease 2019 (COVID-19)-associated 17 18 mortality, but evidence has been inconclusive and limited to hospitalized older individuals. 19 Using data from the UK Biobank, we assessed whether frailty and comorbidity predict COVID-20 19 mortality in the overall community population (n=437,555) and in a selected COVID-19 21 positive sample (n=2.059). Frailty was assessed using the Rockwood Frailty Index (FI) and the Hospital Frailty Risk Score (HFRS), whereas comorbidity was assessed by the Charlson 22 23 Comorbidity Index (CCI). Overall, 408 individuals died of COVID-19, as ascertained from the 24 death register data. In the full sample, HFRS (odds ratio [OR] 1.07; 95% confidence interval [CI] 25 1.06–1.07) and CCI (OR 1.14; 95% CI 1.08–1.20) were associated with increased risk of COVID-26 19 mortality, while FI was not statistically significantly different from null in the multivariable 27 logistic regression model. Adding HFRS or CCI to a model with only age and sex resulted in 28 significantly larger areas under the receiver operating characteristic curves. Nevertheless, 29 when restricting the analyses to COVID-19 positive cases, which is a sample with over-30 representation of frail individuals, neither of the frailty measures or CCI added meaningful 31 predictive accuracy on top of age and sex. Besides, we observed stronger associations 32 between HFRS categories and COVID-19 mortality in relatively younger (<75 years) than older 33 individuals (≥75 years). Our results suggest that HFRS and CCI, which could be readily derived 34 from medical records, may be useful for COVID-19 mortality risk stratification in the 35 community.

36

37 Keywords: COVID-19, mortality, frailty, comorbidity, ageing

38 Introduction

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 39 40 coronavirus 2 (SARS-CoV-2), has led to a global pandemic, affecting more than 41 million individuals and causing ~1.1 million deaths worldwide as of 22nd October 2020 [1]. 41 42 Accumulating evidence has shown that older age, male sex, comorbidities (e.g. diabetes, 43 hypertension), social deprivation, black ethnicity, and laboratory indicators such as elevated 44 levels of d-dimer and interleukin 6 are risk factors for mortality associated with COVID-19 [2-45 6]. However, there are relatively few data available for risk stratification in community 46 samples compared to hospitalized patients.

47 Frailty, characterized as a state of increased vulnerability due to cumulative decline in 48 multiple physiological systems [7], has consistently shown to be a strong predictor of mortality 49 in the general population [8–10]. Various tools have been developed for measuring frailty. 50 Some of which require assessment by physicians, such as the Clinical Frailty Scale (CFS) [11], 51 which is more suitable in clinical settings. Another widely used measure is the Rockwood 52 frailty index (FI), which is defined as a ratio of accumulated deficits over the total number of 53 deficits considered [12]. The Hospital Frailty Risk Score (HFRS), constructed based on the 54 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision 55 (ICD-10) coding system [13], was developed for frailty risk stratification among older 56 hospitalized patients and has been validated for its ability to predict adverse outcomes in various settings [14,15]. 57

A growing number of studies have investigated the association between frailty, frequently measured using the CFS in hospital settings, and mortality among COVID-19 patients, but findings remain inconclusive. While there is evidence that frailty may add to the risk prediction in hospitalized patients [16–19], some studies have observed weak [20,21], or

even null associations [22]. Heterogeneity in the prior results may partly be owing to the COVID-19 patients being a non-random, selected sample with a particularly high prevalence of frailty [23], potentially causing selection bias [24]. With the continuing spread of the SARS-CoV-2 across the world, it is of importance to assess whether COVID-19 mortality can be predicted using other frailty and comorbidity measures, such as the HFRS and CCI that can be readily derived from medical records, in community samples.

68 Using a large population cohort from the UK Biobank study, we aimed to investigate 69 the predictive ability of frailty, measured using the HFRS and FI, and the Charlson Comorbidity 70 Index (CCI) as a measure of comorbidity, for COVID-19 mortality among (a) the overall 71 community population and (b) COVID-19 positive individuals. Our goal was to assess whether 72 an easily accessible frailty and/or comorbidity measure could aid in COVID-19 mortality risk 73 stratification in community settings. In keeping with the observations that higher levels frailty 74 carry a relatively greater risk of all-cause mortality in younger than older ages [9,10,25], we 75 additionally assessed whether the same holds true for COVID-19 mortality. As excess mortality 76 due to COVID-19 may be more pronounced in younger and fitter individuals compared to old 77 and frail [22], it is essential to identify the factors contributing to this risk.

78

79 Methods

80 Study population

This is a population-based cohort study using data from the UK Biobank. Between 2006 and 2010, more than 500,000 participants completed a touch-screen questionnaire, had physical measurements taken, and provided biological samples at one of the 22 assessment centres in England, Wales or Scotland [26]. The UK Biobank study was approved by the North West Multi-

85 Centre Research Ethics Committee. All participants provided written informed consent for86 data collection, analysis, and record linkage.

We excluded participants who died before 1st March 2020, requested to withdraw from the study prior to August 2020, and had missing data on frailty and comorbidity measures. This resulted in a sample size of *n*=437,555, which we referred to as the "full sample". The subgroup of "COVID-19 positive sample" (*n*=2,059) consisted of those being tested positive, diagnosed as COVID-19 patients in hospitals, and/or died of COVID-19. Analyses were performed in both samples (**Fig. 1**).

93

94 COVID-19 diagnosis and mortality

95 Information on COVID-19 was obtained from three data sources linked to UK Biobank: laboratory test results, inpatient medical records, and death register. SARS-CoV-2 PCR test 96 97 results were provided by Public Health England [27], with data available in England only, between 16th March and 24th August 2020. Hospital inpatient data were sourced from the 98 99 Hospital Episode Statistics (HES), containing electronic medical records (i.e., ICD-10 diagnostic codes) for all hospital admissions to National Health Service (NHS) hospitals in England up to 100 30th June 2020. Death register data included all deaths up until 24th August 2020 in England, 101 102 Wales and Scotland, containing ICD-10 codes assigned as individuals' primary and contributory 103 causes of death.

Participants were considered "COVID-19 positive" when meeting at least one of the following criteria: (i) being positive in at least one of the PCR tests; (ii) shown as COVID-19 inpatients, with ICD-10 code U07 in hospital admission; and (iii) died of COVID-19, defined as those with COVID-19 (ICD-10 code U07) as the primary or contributory causes of death. COVID-19 mortality was used as the main outcome in the analyses.

Among the COVID-19 positive individuals, we compared characteristics of those diagnosed as patients (i.e., with positive test result or was a COVID-19 inpatient; *n*=1,970) and those died of COVID-19 but without positive test record (*n*=89), and found that both groups were generally comparable except that individuals in the latter group were more likely to be older, with lower income and with higher HFRS (*Appendix* Table S1).

114

115 Frailty and comorbidity measures

116 Frailty was assessed using the FI and HFRS, and comorbidity was measured using the CCI 117 (timeline of data collection is shown in *Appendix Fig. S1*). The FI has previously been created 118 and validated by us for the UK Biobank participants, using 49 self-reported frailty items 119 assessed at baseline during 2006–2010 that cover a wide range of items for physical and 120 mental well-being (Appendix Table S2) [10]. The FI was calculated as the sum of the items 121 (deficits) present in an individual divided by the total number of deficits, for instance, an 122 individual with 7 deficits from 49 items would receive an FI of 7/49=0.14. The FI was used as 123 both continuous and categorical variable, the latter being categorized into four groups: 124 relatively fit (≤0.03), less fit (>0.03–0.1), least fit (>0.1–0.21) and frail (>0.21) [28]. HFRS and 125 CCI were computed based on the ICD-10 codes from hospital records [13,29]. Only medical 126 records before 1st March 2020 were included so that diagnoses due to or associated with 127 COVID-19 would not bias the results. The HFRS was derived based on 109 frailty-related ICD-10 codes, as previously described by Gibert et al (Appendix Table S3) [13]. While it was 128 129 originally developed for older individuals (≥75 years) who had been admitted to hospital 130 during the prior 2 years, we utilized all available ICD-10 codes for each individual for 131 calculation. Each of the 109 codes were assigned a weight ranging from 0.1 to 7.1, depending 132 on its strength of association with frailty. HFRS was then calculated by summing all the

133 weighted codes, and used both as continuous and categorical measures, the latter being 134 categorized into low (<5), intermediate (5–15) and high (>15) risk of frailty [13]. Similarly, CCI 135 was derived by summing weighted ICD-10 codes, based on 17 comorbidities with weights from 1 to 6 depending on disease severity and mortality risk (Appendix Table S4) [29], and was 136 137 treated as a continuous variable in all analyses. Individuals who had missing hospital data were 138 those who had not been hospitalized or resided outside England (these data were only 139 available for England). To maximize data utilization, we first excluded individuals who 140 attended baseline assessment in Wales or Scotland and with missing hospital data, and then 141 coded the remaining individuals with missing hospital data as 0 for HFRS and CCI. As a 142 sensitivity analysis, we assessed whether including diagnoses from long ago would affect the 143 results by calculating 2-year HFRS and CCI scores using diagnoses assigned only during the past two years (i.e., between 1st March 2018 and 29th February 2020). The FI, HFRS and CCI 144 145 correlated moderately with each other (*Appendix* Table S5).

146

147 Other study variables

Demographic characteristics (e.g. birth year, sex, ethnicity, smoking status) and 148 149 socioeconomic indicators (e.g. education, income, Townsend deprivation index) were 150 collected at baseline during 2006–2010. Education was assessed by the highest self-reported 151 qualification and categorized into low (no relevant qualifications), intermediate (A levels, O levels/GCSEs, CSEs, NVQ/HND/HNC, other professional qualifications) and high (college or 152 153 university degree). Annual household income was self-reported and categorized into four 154 groups (<£18,000, £18,000–30,999, £31,000–51,999, ≥£52,000). Townsend deprivation index was derived from national census data regarding unemployment, car ownership, home 155

ownership, and household overcrowding; higher scores correspond to higher level ofsocioeconomic deprivation.

158

159 *Statistical analyses*

Descriptive statistics were calculated for the full sample and COVID-19 positive sample. Due to the apparent over-representation of frail individuals in the COVID-19 positive sample, we performed logistic regression to formally ascertain if frailty and comorbidity were determinants for being COVID-19 positive.

164 In both samples, multivariable logistic regression models were applied to investigate 165 the associations of frailty and comorbidity (FI, HFRS, CCI, as continuous measures) with COVID-166 19 mortality, adjusted for age (as linear effect, after confirming that the age-mortality 167 relationship was approximately linear) and sex. Ethnicity, smoking status, and socioeconomic 168 variables were subsequently added into the models to test whether they had an effect on the 169 associations. Areas under the receiver operating characteristic curves (AUROC) were used to 170 assess the predictiveness of the different measures. Because the HFRS was originally designed 171 for individuals older than 75 years and previous studies have reported age-varying risks for 172 frailty [9,10,25], we additionally stratified the analysis by age <75 and \geq 75 years, as well as 173 performed an analysis with an interaction term between HFRS (continuous) and age group.

We further performed a series of sensitivity analyses to assess the robustness of our findings, which included (i) using categorical instead of continuous FI and HFRS variables; (ii) using 2-year HFRS and CCI, constructed by ICD-10 codes from the past 2 years only; and (iii) performing multinomial logistic regression models to account for non-COVID-19 deaths as competing risk, where mortality due to COVID-19 or other causes than COVID-19 were compared to those who were alive as of 24 August 2020.

180 To account for multiple comparisons, the Benjamini-Hochberg false discovery rate 181 method was applied [30]. All analyses were performed using Stata v16.0 (Stata Corp, College 182 Station, TX) and R v3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

183

184 Results

185 Sample characteristics

186 Table 1 shows the characteristics of participants in the full sample and COVID-19 positive 187 sample. In the full sample of 437,555 participants, the mean age as of the year 2020 was 68.1 188 (standard deviation [SD] 8.1) and 55.3% were women. The proportions of men, Black ethnicity, 189 previous or current smokers, low education, lowest income and most deprived groups were 190 higher in the COVID-19 positive sample than the full sample. Frailty appeared to be overrepresented among COVID-19 positive individuals, with 21.6% being "frail" (assessed by FI) 191 192 and 22.4% being "high frailty risk" (assessed by HFRS), compared to 12.1% and 2.9% in the full 193 sample. Logistic regression models for COVID-19 positivity showed that FI, HFRS, and CCI were 194 all associated with higher risk of being COVID-19 positive, after adjusting for age and sex (Appendix Table S6). 195

196

197 Frailty and comorbidity in predicting COVID-19 mortality

198 In total, 408 individuals died of COVID-19 between 1st March and 24th August 2020. Results for 199 the logistic regression models for COVID-19 mortality are presented in **Table 2**. In the full 200 sample, when each of the measures – FI, HFRS, and CCI were tested separately, they were 201 significantly associated with higher odds of COVID-19 mortality after controlling for age and 202 sex (models 2–4). AUROC for the model including only age and sex was 0.76 (95% confidence 203 interval [CI] 0.74–0.78); adding FI into the model resulted in a slightly larger AUROC of 0.78

204 (95% CI 0.76–0.80), while adding HFRS and CCI yielded significantly larger AUROCs of 0.83 205 (95% CI 0.81-0.86) and 0.82 (95% CI 0.80-0.84) respectively (Fig. 2A). In the multivariable 206 model with both frailty measures and the CCI included (model 5), HFRS (odds ratio [OR] 1.07; 207 95% CI 1.06–1.07) and CCI (OR 1.14; 95% CI 1.08–1.20), but not FI, predicted statistically 208 significantly higher risk of COVID-19 mortality. AUROC of the multivariable model (0.84; 95% 209 CI 0.83–0.87) was similar to the age and sex-adjusted univariable models of HFRS and CCI (Fig. 210 2A). After restricting the sample to COVID-19 positive individuals, all of these associations 211 were attenuated, and the predictive accuracies were decreased. In the fully adjusted model 212 (model 5), only CCI was marginally associated with COVID-19 mortality (OR 1.09; 95% CI 1.01-213 1.14). Frailty and comorbidity did not add predictive value on top of age and sex, as indicated 214 by similar AUROCs across all models (Fig. 2B). We subsequently adjusted for ethnicity, smoking 215 and socioeconomic variables in both samples; associations of frailty and comorbidity with 216 COVID-19 mortality were not affected by these variables (*Appendix* Table S7).

In both samples, compared with older individuals (\geq 75 years), relatively younger individuals (<75 years) had higher ORs for COVID-19 mortality across HFRS categories (**Fig. 3**); there was also significant interaction between HFRS and age in the COVID-19 positive sample (*P*_{interaction}<0.001), but not in the full sample (*Appendix* Table S8). We also tested the interaction between HFRS and sex, yet it was not statistically significant and thus we did not further perform subgroup analysis by sex.

223

224 Sensitivity analyses

The predictive abilities of frailty and comorbidity for COVID-19 mortality were largely similar compared to the main analyses when (i) using FI and HFRS as categorical instead of continuous variables (*Appendix* Table S9), (ii) using the 2-year HFRS and CCI variables instead of the

original scores (*Appendix* Table S10), and (iii) accounting for competing risk by deaths due to
other causes than COVID-19 (*Appendix* Table S11).

230

231 Discussion

232 Using data from the UK Biobank, we found that HFRS and CCI, measures of frailty and 233 comorbidity respectively, were viable predictors of COVID-19 mortality and added predictive 234 value on top of age and sex in the overall community population. The associations persisted 235 even after adjusting for ethnicity, smoking and socioeconomic variables. Nonetheless, among 236 COVID-19 positive individuals who were already more likely to be frail, HFRS and CCI did not 237 improve predictive accuracy for COVID-19 mortality in addition to age and sex. Stronger 238 associations between HFRS and COVID-19 mortality were seen among younger (<75 years) 239 than older individuals (\geq 75 years), indicating that the HFRS may be applicable for predicting 240 mortality risk in younger adults as well.

241 To the best of our knowledge, this is the first study that has assessed the associations 242 between frailty and COVID-19 mortality in the community population. We showed that frailty 243 was associated with an elevated risk of COVID-19 mortality, and that a HFRS constructed 244 based on ICD-10 codes was a stronger predictor than an FI calculated using self-reported data 245 at baseline. The CCI, a measure of comorbidity computed by ICD-10 codes, likewise predicted COVID-19 mortality, which is in line with prior research showing a positive association 246 247 between comorbidity and COVID-19 deaths [18,21,31]. Together, our results imply that frailty 248 and comorbidity measures available in routinely collected medical records may be applied for 249 risk stratification of COVID-19 mortality in the overall community population.

However, the predictive accuracies of frailty and comorbidity for COVID-19 mortality were reduced after restricting the sample to only those with the disease. It has been argued

252 that using non-random samples may induce selection bias in COVID-19-related studies [24]. In 253 our COVID-19 positive sample, there was an over-representation of the most frail individuals, 254 with even greater proportion of the "high frailty risk" group in our sample than in the cohort 255 of older hospitalized individuals in the original HFRS study (22.1% vs 20.0%) [13]. Consistent 256 with a previous study [32], we confirmed that frailty and comorbidities are determinants of 257 being COVID-19 positive in the UK Biobank sample. Such over-representation of frailty may 258 partly explain the inconsistencies in the frailty-mortality associations among hospitalized 259 COVID-19 patients [16–22]. In a relatively frail sample, COVID-19 mortality risk may in fact be 260 more related to other factors, such as viral load and host immune characteristics [20,33]. 261 Indeed, none of our models in the COVID-19 positive sample yielded a good predictive 262 accuracy of AUROC>0.8, even when smoking, ethnicity and socioeconomic variables were 263 included. More research is warranted to identify the most accurate predictors for mortality 264 among COVID-19 patients.

Given that the HFRS was initially developed for older individuals, we stratified the analysis by age and observed a more pronounced association between HFRS and COVID-19 mortality among the younger individuals (<75 years). A similar pattern has also been reported in the literature, in which frailty has shown to be more strongly associated with mortality at younger old ages than the oldest ages [9,25]. Our findings thus highlight the importance of frailty screening in younger individuals in prevention for COVID-19 related mortality.

The large sample of UK Biobank participants with linkage to COVID-19 data enabled us to study the associations among the overall population and to examine the potential effects of sample selection. Nevertheless, there are several caveats to this study. Firstly, demographic variables, socio-economic indicators and the deficits for construction of FI were assessed during baseline in 2006–2010. In particular, the FI, calculated by self-reported data ~10 years

276 ago, may not fully reflect participants' current physiological status. Future research may utilize 277 an FI based on routine primary care data, such as the electronic FI [34], for assessing its 278 predictive ability for COVID-19 mortality among the general population. Secondly, with the 279 limitation of data availability, we were not able to retrieve test results and hospital inpatient 280 data for people living in Scotland or Wales. Thirdly, during the earlier periods of the epidemic, 281 COVID-19 testing in the UK was largely restricted to hospitalized individuals, who have more 282 severe course of the diseases. As such, mild or asymptomatic COVID-19 cases may conceivably 283 be missed, leading to an underestimation of COVID-19 positive cases. Fourthly, we modelled 284 the outcome, COVID-19 mortality, as a binary variable rather than a time-to-event or survival 285 outcome because we could not ascertain the exact date of confirmed COVID-19 infection for 286 several individuals in the COVID-19 positive subsample. However, as the follow-up time was 287 limited, it could be considered essentially complete for most participants (i.e., minimal 288 censoring due to migration and other deaths). Finally, UK Biobank is not a nationally 289 representative sample, with generally healthier and less socioeconomically deprived 290 participants than the UK average [35], thereby reducing the generalizability of our findings.

291

292 Conclusions and implications

In conclusion, HFRS and CCI, measures of frailty and comorbidity respectively, constructed using routinely collected medical records, predicted COVID-19 mortality in the overall community sample and added predictive value on top age and sex. However, similar effects were not seen in those who already have the disease. Our findings suggest that identification of frail individuals in the general population may be a viable strategy for COVID-19 mortality risk stratification.

299 Acknowledgements

- 300 This research was conducted using the UK Biobank resource, as part of the registered project
- 301 22224.
- 302
- 303 Declarations
- 304 Funding: This work was supported by the Swedish Research Council (2018-02077, 2019-
- 305 01272), the Loo & Hans Osterman Foundation, the Strategic Research Program in
- 306 Epidemiology at Karolinska Institutet and the Karolinska Institutet Foundations.
- 307 **Conflicts of interest:** The authors declare that they have no conflict of interest.
- 308 Ethical approval: Ethical approval for this study is covered by the general ethics review for the
- 309 UK Biobank, conducted by North West Multi-Centre Research Ethics Committee (Reference:
- 310 16/NW/0274, 13 May 2016).
- 311 **Consent to participate:** Informed consent was obtained from all individual participants
- 312 included in the study.
- 313 **Consent to publish:** Not applicable.

314 **Availability of data and material:** UK Biobank is an open access resource. All bona fide 315 researchers can apply to use its data for health-related research that is in the public interest

- 316 (http://www.ukbiobank.ac.uk/register-apply).
- 317 **Code availability:** Not applicable.

Authors' contributions: J.K.L.M., R.K.-H., and J.J. contributed to the study concept and design;

319 Y.W., S.H. and J.J. were responsible for acquisition of data; J.K.L.M., R.K.-H. and J.J. analysed

- 320 and interpreted the data; J.K.L.M. and J.J. drafted the manuscript; R.K.-H., Y.W. and S.H.
- 321 critically revised the manuscript for important intellectual content. All authors read and
- 322 approved the final manuscript.

323 References

- 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
- 325 time. Lancet Infect Dis. 2020;20:533–4.
- 326 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
- 327 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
- 328 2020;395:1054–62.
- 329 3. O'Dowd A. Covid-19: People in most deprived areas of England and Wales twice as likely to
- die. BMJ. 2020;369:m2389.
- 4. Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19
- 332 patients. Diabetes Res Clin Pract. 2020;166:108293.
- 333 5. Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk
- factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis: Mortality-
- related risk factors of COVID-19, SARS, and MERS. J. Infect. 2020. p. e18.
- 336 6. Golestaneh L, Neugarten J, Fisher M, Billett HH, Gil MR, Johns T, et al. The association of
- race and COVID-19 mortality. EClinicalMedicine. 2020;25.
- 338 7. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet.
 339 2013;381:752–62.
- 340 8. Grabovac I, Haider S, Mogg C, Majewska B, Drgac D, Oberndorfer M, et al. Frailty Status
- 341 Predicts All-Cause and Cause-Specific Mortality in Community Dwelling Older Adults. J Am
- 342 Med Dir Assoc. 2019;20:1230-1235.e2.
- 343 9. Li X, Ploner A, Karlsson IK, Liu X, Magnusson PKE, Pedersen NL, et al. The frailty index is a
- 344 predictor of cause-specific mortality independent of familial effects from midlife onwards: A
- large cohort study. BMC Med. 2019;17:94.
- 10. Williams DM, Jylhävä J, Pedersen NL, Hägg S. A Frailty Index for UK Biobank Participants.

Journals Gerontol - Ser A Biol Sci Med Sci. 2019;74:582–7.

- 348 11. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global
- 349 clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.
- 350 12. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for
- 351 creating a frailty index. BMC Geriatr. 2008;8:24.
- 352 13. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and

353 validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using

- electronic hospital records: an observational study. Lancet. 2018;391:1775–82.
- 355 14. Kundi H, Wadhera RK, Strom JB, Valsdottir LR, Shen C, Kazi DS, et al. Association of Frailty
- 356 with 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia among
- 357 Elderly Adults. JAMA Cardiol. 2019;4:1084–91.
- 358 15. McAlister F, Van Walraven C. External validation of the Hospital Frailty Risk Score and
- 359 comparison with the Hospital-patient One-year Mortality Risk Score to predict outcomes in
- 360 elderly hospitalised patients: A retrospective cohort study. BMJ Qual Saf. 2019;28:284–8.
- 361 16. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of
- 362 frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational
- 363 cohort study. Lancet Public Heal. 2020;5:e444–51.
- 364 17. Aw D, Woodrow L, Ogliari G, Harwood R. Association of Frailty with Mortality in Older
 365 Inpatients with Covid-19: A Cohort Study. Age Ageing. 2020;1–8.
- 18. Hägg S, Jylhävä J, Wang Y, Xu H, Metzner C, Annetorp M, et al. Age, frailty and comorbidity
 as prognostic factors for short-term outcomes in patients with COVID-19 in geriatric care. J
 Am Med Dir Assoc. 2020;0.
- 369 19. Kundi H, Çetin EHÖ, Canpolat U, Aras S, Celik O, Ata N, et al. The role of Frailty on Adverse
- 370 Outcomes Among Older Patients with COVID-19. J Infect. 2020;

20. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, et al. Frailty and
Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. J
Am Med Dir Assoc. 2020;21:928-932.e1.

374 21. Owen RK, Conroy SP, Taub N, Jones W, Bryden D, Pareek M, et al. Comparing associations

between frailty and mortality in hospitalised older adults with or without COVID-19 infection:

a retrospective observational study using electronic health records. Age Ageing. 2020;1.

22. Miles A, Webb TE, Mcloughlin BC, Mannan I, Rather A, Knopp P, et al. Outcomes from

378 COVID-19 across the range of frailty: excess mortality in fitter older people. Eur Geriatr Med.

379 2020;1:3.

380 23. Collins JT, Short R, Carter B, Verduri A, Myint PK, Quinn TJ, et al. The Clinical Frailty Scale:

381 Estimating the Prevalence of Frailty in Older Patients Hospitalised with COVID-19. The COPE
382 Study. Geriatr (Basel, Switzerland). 2020;5.

383 24. Griffith G, Morris TT, Tudball M, Herbert A, Mancano G, Pike L, et al. Collider bias
384 undermines our understanding of COVID-19 disease risk and severity. medRxiv.

385 2020;2020.05.04.20090506. Available from: https://doi.org/10.1101/2020.05.04.20090506

386 25. Tran DTT, Tu J V., Dupuis JY, Eddeen AB, Sun LY. Association of frailty and long-term survival

in patients undergoing coronary artery bypass grafting. J Am Heart Assoc. 2018;7.

388 26. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
389 Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle

and Old Age. 2015;12:e1001779.

27. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, et al. Dynamic linkage of

392 covid-19 test results between public health england's second generation surveillance system

and uk biobank. Microb Genomics. 2020;6:1–9.

394 28. Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult

395 lifespan: Evidence from the Canadian National Population Health Survey. CMAJ.396 2011;183:E487-94.

- 397 29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
- 398 comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–

399 83.

- 30. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
 Approach to Multiple Testing. J R Stat Soc Ser B. 1995;57:289–300.
- 402 31. Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo C-L, Kuchel GA, et al. Preexisting
- 403 Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort.
- 404 Journals Gerontol Ser A. 2020;75:2224–30.
- 405 32. Woolford SJ, D'Angelo S, Curtis EM, Parsons CM, Ward KA, Dennison EM, et al. COVID-19
- and associations with frailty and multimorbidity: a prospective analysis of UK Biobank
 participants. Aging Clin Exp Res. 2020;32:1897–905.
- 408 33. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients
- 409 With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020;71:1393–9.
- 410 34. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation
- 411 of an electronic frailty index using routine primary care electronic health record data. Age
- 412 Ageing. 2016;45:353–60.
- 413 35. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
- 414 Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those
- 415 of the General Population. Am J Epidemiol. 2017;186:1026–34.

Tables and Figures

	Full sample	COVID-19 positive sample	
	(n=437,555)	(n=2,059)	
Deaths, n (%)	2,146 (0.5)	477 (23.2)	
Age (years), mean ± SD	68.1 ± 8.1	68.8 ± 9.0	
Sex, n (%)			
Women	241,791 (55.3)	976 (47.4)	
Men	195,764 (44.7)	1,083 (52.6)	
Ethnicity, n (%)			
White	411,094 (94.3)	1,798 (87.7)	
Asian	10,471 (2.4)	94 (4.6)	
Black	7,608 (1.7)	102 (5.0)	
Others	6,886 (1.6)	57 (2.8)	
Smoking status, n (%)			
Never	242,414 (55.6)	5.6) 981 (48.0)	
Previous	150,245 (34.5)	806 (39.5)	
Current	43,346 (9.9)	256 (12.5)	
Education, n (%)			
Low	70,461 (16.4)	512 (25.6)	
Intermediate	218,540 (50.9)	999 (50.0)	
High	140,713 (32.8)	489 (24.5)	
Income, n (%)			
<£18,000	81,674 (22.0)	564 (33.5)	
£18,000-30,999	94,319 (25.4)	438 (26.0)	
£31,000–51,999	98,079 (26.4)	372 (22.1)	
≥£52,000	97,456 (26.3)	311 (18.5)	
Townsend deprivation quintile, n (%)			
1 (least deprived)	87,712 (20.1)	291 (14.1)	
2	88,844 (20.3)	334 (16.2)	
3	88,525 (20.3)	375 (18.2)	
4	87,596 (20.0)	431 (20.9)	
5 (most deprived)	84,352 (19.3)	627 (30.5)	
Frailty Index, median (IQR)	0.112 (0.066–0.163)	0.133 (0.083–0.199)	
By category, n (%):	, , , , , , , , , , , , , , , , , , ,	· · · · ·	
Relatively fit (≤0.03)	26,412 (6.0)	78 (3.8)	
Less fit (>0.03–0.1)	164,761 (37.7)	604 (29.3)	
Least fit (>0.1–0.21)	193,409 (44.2)	933 (45.3)	
Frail (>0.21)	52,973 (12.1)	444 (21.6)	
Hospital Frailty Risk Score, median (IQR)	0.7 (0–3.2) 3.2 (0–12.9)		
By category, n (%):			
Low risk (<5)	365,958 (83.6)	1,196 (58.1)	
Intermediate risk (5–15)	59,046 (13.5) 402 (19.5)		
High risk (>15)	12,551 (2.9)		
Charlson Comorbidity Index, median (IQR)	0 (0-1)	1 (0-3)	

Table 1 Characteristics of UK Biobank participants in the full sample and COVID-19 positive sample

IQR, interquartile range; SD, standard deviation

Table 2 Logistic regression models for the associations of age, sex, frailty and comorbidity with COVID-19 mortality in the full sample and COVID-19 positive sample

	Model 1: age + sex OR (95% CI)	Model 2: FI + age + sex OR (95% CI)	Model 3: HFRS + age + sex OR (95% CI)	Model 4: <u>CCI + age + sex</u> OR (95% CI)	Model 5: Multivariable OR (95% CI)
(a) Full sample (<i>n</i> =437,555)					
Age	1.14 (1.12–1.16)*	1.13 (1.11–1.15)*	1.11 (1.09–1.13)*	1.11 (1.09–1.13)*	1.10 (1.09–1.12)*
Male sex	1.99 (1.63–2.44)*	2.12 (1.73–2.59)*	1.93 (1.57–2.36)*	1.77 (1.45–2.17)*	1.86 (1.52–2.29)*
FI (per 10% increase)		1.70 (1.52–1.90)*			1.09 (0.96–1.23)
HFRS			1.08 (1.07–1.09)*		1.07 (1.06–1.07)*
CCI				1.40 (1.35–1.45)*	1.14 (1.08–1.20)*
Area under the ROC curve	0.76 (0.74–0.78)	0.78 (0.76–0.80)	0.83 (0.81–0.86)	0.82 (0.80–0.84)	0.84 (0.83–0.87)
(b) COVID-19 positive sample (<i>n</i> =2,059)					
Age	1.12 (1.10–1.14)*	1.12 (1.10–1.14)*	1.11 (1.09–1.13)*	1.11 (1.10–1.13)*	1.11 (1.09–1.13)*
Male sex	1.45 (1.14–1.83)*	1.47 (1.16–1.87)*	1.44 (1.14–1.83)*	1.43 (1.13–1.81)*	1.43 (1.12–1.81)*
FI (per 10% increase)		1.09 (0.96–1.25)			1.00 (0.87–1.15)
HFRS			1.01 (1.00–1.02)*		1.01 (1.00–1.01)
CCI				1.09 (1.04–1.15)*	1.09 (1.01–1.14)*
Area under the ROC curve	0.74 (0.72–0.77)	0.74 (0.72–0.77)	0.75 (0.72–0.77)	0.75 (0.72–0.77)	0.75 (0.72–0.77)

CCI, Charlson comorbidity index; CI, confidence interval; FI, Frailty Index; HFRS, Hospital Frailty Risk Score; OR, odds ratio; ROC, receiver operating characteristic curve.

*Significant with a false discovery rate corrected significance level at 0.044




Fig. 1 Flowchart of selection of study sample from the UK Biobank




Fig. 2 Receiver operating characteristic (ROC) curves for age, sex, frailty and comorbidity in predicting COVID-19 mortality. **(A)** Analyses performed in the full UK Biobank sample (*n*=437,555); **(B)** analyses performed in the COVID-19 positive sample (*n*=2,059). Model 1 to model 4 are univariable logistic regression models adjusted for age and sex, while model 5 is the multivariable logistic regression model. AUC, area under the receiver operating characteristic curves; CCI, Charlson comorbidity index; FI, Frailty Index; HFRS, Hospital Frailty Risk Score

All rights reserved. No reuse allowed without permission.




Fig. 3 Associations between Hospital Frailty Risk Score and COVID-19 mortality stratified by age into younger (<75 years) and older (\geq 75 years) individuals in full sample (*n*=437,555) and in COVID-19 positive sample (*n*=2,059). Error bars indicate 95% confidence intervals. Models were adjusted for sex.

Note: The point estimates for the stratified analysis can be found in Appendix Table S8